Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT04816773

Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the European Union (EU). MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur. These components are used along with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert components that is marketed in the European Union (EU). This type of data collection is required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

MSK Doctors, The Keep Clinic, Grantham, Lincolnshire, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has previously undergone or currently has determined to undergo a primary TKA with the specified combination of components: EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert
  • Has previously undergone or currently has determined to undergo a primary TKA for any of the following:
  • non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;
  • inflammatory degenerative joint disease including rheumatoid arthritis;
  • correction of functional deformity;
  • Willing to voluntarily sign the informed consent form
  • Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit.
  • Previously implanted subjects must be enrolled within 14 months of their primary TKA implantation.

Prospective enrollment of a previously unimplanted contralateral knee is permitted in this study provided:

  • the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) are used,
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  • the subject agrees to a second Informed Consent document and data collection specific to the second TKA.

Bilateral subjects can have both TKAs enrolled in the study provided:

  • the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) were implanted in both,
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  • the subject agrees to a second Informed Consent document and data collection specific to the second TKA.

Bilateral implantation can occur at different time periods for the same subject.

Exclusion criteria

  • Skeletally immature (less than 21 years of age) at time of implantation
  • Has or had an overt infection at the time of implantation
  • Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation
  • Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation
  • Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
  • Currently enrolled in another clinical investigation which could affect the endpoints of this protocol
  • Has documented substance abuse issues
  • Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  • Currently incarcerated or has impending incarceration
  • Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol

Treatment and study plan

EVOLUTION® NitrX™

Device

EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Primary outcomes

  1. Component Survivorship of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia

    Time frame: 10 years post-operative

    The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year

  2. Component Survivorship of the EVOLUTION® NitrX™ CS/CR Non-Porous Femur

    Time frame: 10 years post-operative

    The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ CS/CR Non-Porous Femur out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year.

  3. Component Survivorship of the EVOLUTION® NitrX™ MP CS tibial inserts

    Time frame: 10 years post-operative

    The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ MP CS tibial inserts out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year.

Secondary outcomes

  1. Functional Scores

    Time frame: 10 years post-operative

    To assess functional scores utilizing Knee Injury and Osteoarthritis Outcome Score (KOOS).

  2. Functional Scores

    Time frame: 10 years post-operative

    To assess functional scores utilizing EQ-5D-5L.

  3. Functional Scores

    Time frame: 10 years post-operative

    To assess functional scores utilizing Forgotten Joint Score (FJS).

  4. Subject Satisfaction

    Time frame: 10 years post-operative

    To assess subject satisfaction with their TKA procedure via the Satisfaction Survey.

  5. Radiolucencies

    Time frame: 10 years post-operative

    To assess the presence of radiolucencies surrounding the implanted femoral and tibial components present in each of the 17 zones.

  6. To assess subject safety: Adverse Events

    Time frame: 1, 3, 5, 7, 10 years

    To assess safety of the EVOLUTION® NitrX™ system through device-related adverse event findings and/or adverse device effects during follow-up visits.

  7. To assess device tolerability within subject: Adverse Events

    Time frame: 10 years post-operative

    To assess tolerability of the EVOLUTION® NitrX™ system service-related adverse event findings and/or adverse device effects during follow-up visits.

Sponsors and collaborators

Lead sponsor

MicroPort Orthopedics Inc.

Industry

Registry information

Important dates

Study start
2022
Primary completion
2034
Study completion
2035
First posted
Mar 25, 2021
Registry last updated
Mar 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.